S

SCAFFIDI L.

Last name: SCAFFIDI L.

2020 (v1)

Publication

Metadata-only

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Polverelli N. Elli E. M. Abruzzese E.

Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs). We analyzed the incidence, risk factors and outcome of SPMs in 700 MF patients treated with RUX in a real-world...

Uploaded on: April 14, 2023
2021 (v1)

Publication

Metadata-only

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome

Palandri F. Tiribelli M. Breccia M.

BACKGROUND: After ruxolitinib discontinuation, the outcome of patients with myelofibrosis (MF) is poor with scarce therapeutic possibilities. METHODS: The authors performed a subanalysis of an observational, retrospective study (RUX-MF) that included 703 MF patients treated with ruxolitinib to investigate 1) the frequency and reasons for...

Uploaded on: March 27, 2023
2021 (v1)

Publication

Metadata-only

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Palandri F. Palumbo G. A. Elli E. M.

No description

Uploaded on: April 14, 2023